21:13 , Apr 17, 2018 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: 3-D models; pharmacokinetics/pharmacodynamics 3-D human intestinal organoids could be used to test the PK properties of drug compounds. The organoids are generated by culturing human induced pluripotent stem (iPS) cells in a medium containing fibroblast...
18:58 , Feb 8, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3D models Fundus organoids derived from human pluripotent stem cells could be used to screen therapies for peptic ulcers and other gastric diseases. The organoids were generated by culturing human pluripotent stem cells in a...
07:00 , May 25, 2015 |  BC Week In Review  |  Company News

Taxus Cardium, Shenzhen Qianhai Taxus Insdustry Capital Management deal

Taxus Cardium granted Shenzhen the first right to negotiate for an exclusive license to develop and commercialize three Taxus products in Asian countries. The products include Generx alferminogene tadenovec, an adenoviral vector carrying the...
07:00 , May 4, 2015 |  BC Week In Review  |  Company News

Taxus Cardium, Dr. Reddy’s Laboratories Ltd. deal

Taxus granted Dr. Reddy’s exclusive rights to co-develop and commercialize Generx cardionovo alferminogene tadenovec in the Commonwealth of Independent States (CIS), Venezuela, Vietnam and Myanmar. Dr. Reddy’s also has the right of first...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Clinical News

Generx cardionovo alferminogene tadenovec: Interim Phase III data

Interim data from 11 patients with myocardial ischemia due to coronary artery disease (CAD) in the open-label, Russian Phase III ASPIRE trial showed that an intracoronary infusion of Generx led to a 24.4% improvement in...
07:00 , Apr 10, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lymphoma Jagged 1 (JAG1); notch 2 (NOTCH2); fibroblast growth factor 4 (FGF4); fibroblast growth factor receptor 1 (FGFR1;...
08:00 , Mar 6, 2014 |  BC Innovations  |  Targets & Mechanisms

Heart cells: no longer undivided

The inability of adult heart cells to divide rapidly enough to repair cardiac damage has been a major impediment to regenerating heart tissue and preventing fibrosis after myocardial infarction. Now, a U.S. team has used...
08:00 , Feb 27, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Stimulus-triggered acquisition of pluripotency (STAP) cells derived from adult mouse somatic cells Methods to...
08:00 , Feb 27, 2014 |  BC Innovations  |  Tools & Techniques

(Pluri)potent acid

Academics and companies alike are scrambling-and thus far failing-to reproduce a surprisingly simple method for generating pluripotent mouse stem cells that uses an external stress stimulus to trigger reprogramming. Whether the method simply does not...
07:00 , Oct 16, 2000 |  BC Week In Review  |  Clinical News

Genvascor: Phase I/II trials update

Collateral Therapeutics Inc. (CLTX), San Diego, Calif.   Product: Genvascor   Business: Gene/Cell therapy, Cardiovascular   Therapeutic category: Gene therapy, Angiogenesis   Target: Endothelial cells   Description: Adenoviral vector encoding fibroblast growth factor 4 (FGF-4)   Indication: Treat peripheral...